Polycyclo Ring System Patents (Class 514/185)
  • Patent number: 10500609
    Abstract: A process of providing an antibacterial coating to the surface of an article including the steps of applying a layer of an antibacterial precursor layer to the surface of an article to which an antibacterial coating is to be applied, wherein said antibacterial precursor layer is a precursor from which the coating is to be formed; and directing a neutral molecular hydrogen flux from a neutral molecular hydrogen flux emission source towards the surface of the article. Upon impact of neutral hydrogen molecules on molecules at or on the surface of an article, the bonds of the antibacterial precursor layer are selectively ruptured, and wherein the selectively ruptured bonds cross-link with themselves or with other chemical moieties at said surface or a combination thereof, resulting an antibacterial coating being formed on the surface of the article.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 10, 2019
    Assignee: MASTER DYNAMIC LIMITED
    Inventors: Yingnan Wang, Zhuonan Miao, Ching Tom Kong, Woon Ming Lau, Sui Kong Hark, Ka Wai Wong
  • Patent number: 10493081
    Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: December 3, 2019
    Assignee: Galera Labs, LLC
    Inventors: Jeffery L. Keene, Dennis P. Riley, Robert A. Beardsley
  • Patent number: 10450322
    Abstract: The present invention relates to carboxamide halogenated porphyrin derivatives, in particular bacteriochlorin or chlorin, of formula (I) use of the same or a pharmaceutically acceptable salt thereof in photodynamic therapy, where the derivatives are able to detect and exhibit the presence of hyperproliferative disorders and, in the presence of an adequate lighting, to treat the same. The present invention also describes a pharmaceutical composition having the carboxamide halogenated porphyrin derivatives, in particular bacteria-chlorin or chlorin, of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of cancer and/or microbial and/or viral infections, in humans or animals.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: October 22, 2019
    Assignees: LUZITIN, S.A., UNIVERSIDADE DE COIMBRA
    Inventors: Goncalo Pereira Nascimento Costa, Nuno Paulo Ferreira Goncalves, Carlos Jorge Pereira Monteiro, Artur Carlos Reis De Abreu, Helder Tao Ferraz Cardoso Soares, Luis Gabriel Borges Rocha, Fabio Antonio Schaberle, Maria Miguens Pereira, Luis Guilherme Da Silva Arnaut Moreira
  • Patent number: 10406167
    Abstract: The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 10, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jonathan L. Sessler, Jonathan Arambula, Zahid H. Siddik, Gregory Thiabaud
  • Patent number: 10358455
    Abstract: Disclosed is an arene ruthenium complex with R1, R2, R3, and piperidine as main ligands, preparation method and utilization thereof. R1, R2, R3 are selected from —H, —Cl, —F, —Br, —I, —CF3, —NO2, —OCH3, —OH, —COOH, —CH3, —N(CH3)2, —C2H2, —SO2CH3, alkane with 1 to 6 carbon atoms, substituted alkyl with 1 to 6 carbon atoms, phenyl, substituted phenyl, pyridyl, substituted pyridyl, furyl, substituted furyl, pyrrolyl, substituted pyrrolyl, thiazyl or substituted thiazyl group respectively. The substituted groups in the substituted phenyl, substituted pyridyl, substituted furyl, substituted thiazyl and substituted pyrrolyl are selected from hydroxyl, nitro, halogen, amido, carboxyl, cyano, thiol or naphthene group with 3 to 8 carbon atoms, SO3H, alkane with 1 to 6 carbon atoms, alkenyl with 2 to 6 carbon atoms, alkyne with 2 to 6 carbon atoms, C1-C6 hydroxyalkane, C1-C6 aminoalkane, CO2R?, CONR?R?, COR?, SO2R?R?, C1-C6 alkoxyl, C1-C6 alkyl thiol, —N?NR?, NR?R? or C1-C6 trifloroalkyl.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: July 23, 2019
    Assignee: GUANGDONG PHARMACEUTICAL UNIVERSITY
    Inventor: Wenjie Mei
  • Patent number: 10335608
    Abstract: A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a photodynamic compound containing at least one transition metal; and (b) irradiating the photodynamic compound in the organism with electromagnetic radiation, wherein the electromagnetic radiation includes ionizing radiation and is effective to activate the photodynamic compound to destroy at least one of the cells and the microorganisms in the organism. The ionizing radiation is preferably X-rays and/or gamma rays. The non-ionizing radiation is preferably light in the range from 600-950 nm.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: July 2, 2019
    Assignees: THERALASE TECHNOLOGIES, INC., UNIVERSITY HEALTH NETWORK
    Inventors: Arkady Mandel, Carl Fisher, Lothar Lilge
  • Patent number: 10328085
    Abstract: The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem cells in peripheral blood for subsequent isolation in the process of apheresis and allogeneic or autologous transplantation.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: June 25, 2019
    Assignee: UNIWERSYTET JAGIELLONSKI
    Inventors: Agata Szade, Krzysztof Szade, Alicja Jozkowicz, Jozef Dulak
  • Patent number: 10166222
    Abstract: This invention is directed to derivatives of piperidine-2,6-dione, or their organic or inorganic salts thereof, a methods of synthesis of these derivatives, and their application as active pharmaceutical ingridient as inhibitors of TNF? releasing in cells, the derivative of piperidine-2,6-dione being of the general formula (I): wherein n represents 1, 2, 3, 4, 5 or 6; R1 represents from one to four of the same or different substituents selected from F, Cl, Br, C1-4 alkyl, OH, OC1-4 alkyl, NO2, NHC(O)C1-4 alkyl, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2; R2 represents OR3, NR3R4, N(R3)COR4, O2CR5; R3 and R4 represent independently and at each occurrence H or C1-4 alkyl; R5 represents CHR6NR7R8, CHR6NR9C(O)CHR10NR7R8, a heterocycle W or CHR6NR9C(O)W; R6, R9, R10 represent independently and at each occurrence H, or C1-4 alkyl; R7 and R8 represent independently and at each occurrence H, C1-4 alkyl, or R7 and R8 taken together represent 1,3-propylene, 1,4-butylene, 1,5-pentylene , or 1,6-hexylene; W represents four-
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 1, 2019
    Assignee: Tianjin Hemay Bio-Tech Co., Ltd.
    Inventor: Hesheng Zhang
  • Patent number: 10111842
    Abstract: Provided herein are photosensitizer compounds for use in a variety of clinical, industrial, and research applications. In particular, provided are deep eutectic solvents and natural deep eutectic solvents for use in killing of bacteria.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: October 30, 2018
    Assignee: University of Oslo
    Inventors: Hanne Hjorth Tønnesen, Kristine Opsvik Wikene
  • Patent number: 10080759
    Abstract: A method of treating pruritus (itching) in a subject in need thereof is carried out by administering the subject an active agent in a treatment effective amount, wherein the active agent is a superoxide dismuate (SOD) mimetic. The SOD mimetic can be a complex of a metal (e.g., manganese) and an organic ligand, with suitable organic ligands including porphyrins, polyamines, salens, nitroxides, and fullerenes. Compositions for carrying out such methods are also described.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: September 25, 2018
    Assignees: Duke University, BioMimetix J.V., LLC
    Inventors: Ru-Rong Ji, Tong Liu, Ines Batinic-Haberle, David S. Warner, Kimberly C. Stone, James D. Crapo
  • Patent number: 10010557
    Abstract: The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem cells in peripheral blood for subsequent isolation in the process of apheresis and allogeneic or autologous transplantation.
    Type: Grant
    Filed: May 9, 2015
    Date of Patent: July 3, 2018
    Assignee: UNIWERSYTET JAGIELLONSKI
    Inventors: Agata Szade, Krzysztof Szade, Alicja Jozkowicz, Jozef Dulak
  • Patent number: 9969759
    Abstract: Disclosed herein are organometallic complexes and methods of using the same in detecting double stranded DNA or RNA, selectively over single stranded DNA or RNA.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: May 15, 2018
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, Chad M. Shade, Robert D. Kennedy, Jessica Lynn Rouge, Soyoung E. Seo, Mary X. Wang
  • Patent number: 9969858
    Abstract: A composition including a metalloinsertor conjugate that specifically targets mismatch repair (MMR)-deficient cells includes a complex represented by Formula I. Mm+(L1)(L2)(L3)(L4)(L5)??Formula I Selective cytotoxicity may be induced in MMR-deficient cells upon uptake of the metalloinsertor conjugate. Metalloinsertor complexes conjugated with platinum (Pt) may allow for more specific targeting of platinum anticancer agents.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: May 15, 2018
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Alyson Weidmann, Jacqueline K. Barton
  • Patent number: 9867391
    Abstract: The present invention generally relates to the field of medical nutrition. For example, the present invention provides a composition that can be used to treat, prevent and/or reverse muscle atrophy related to immobilization and its consequences. One embodiment of the present invention concerns a composition comprising a leucine and antioxidants that can be used in accelerating muscle recovery after muscle atrophy.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: January 16, 2018
    Assignee: Nestec S.A.
    Inventors: Dominique Dardevet, Isabelle Savary-Auzeloux, Didier Remond, Lydie Combaret, Gary Williamson, Magali Faure, Denis Breuille
  • Patent number: 9855279
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: January 2, 2018
    Assignee: GALERA LABS, LLC
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • Patent number: 9765103
    Abstract: The present invention relates to using a versatile synthetic approach to generate a new class of ester, amido, or carbamate prodrugs of highly potent, but systemically too toxic, platinum-acridine anticancer agents. The new hybrids contain a hydroxyl group, which has been masked with a cleavable lipophilic acyl moiety. Both butanoic (butyric) and bulkier 2-propanepentanoic (valproic) esters were introduced to these compounds. The goal of this design was to improve the drug-like properties of the pharmacophore (e. g., log D) without compromising its DNA-mediated cell kill potential. Two distinct pathways by which the target compounds undergo effective ester hydrolysis, the proposed activating step, have been confirmed: platinum-mediated, self-immolative ester cleavage in a low-chloride environment (LC-ESMS, NMR spectroscopy) and enzymatic cleavage by human carboxylesterase-2 (hCES-2) (LC-ESMS).
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: September 19, 2017
    Inventors: Ulrich Bierbach, Song Ding
  • Patent number: 9603928
    Abstract: The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: March 28, 2017
    Assignees: SBI Pharmaceuticals Co., Ltd., Osaka City University
    Inventors: Masahiro Ishizuka, Urara Oto, Atsuko Kamiya, Kiwamu Takahashi, Tohru Tanaka, Toshiyuki Ozawa, Kuniyuki Morimoto, Keitaro Watanabe
  • Patent number: 9592219
    Abstract: A new self-magnetic metal-salen complex compound and its derivatives are provided. The present invention is a metal-salen complex compound including any one of the following compounds.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: March 14, 2017
    Assignees: IHI Corporation
    Inventors: Yoshihiro Ishikawa, Haruki Eguchi
  • Patent number: 9572795
    Abstract: This invention relates to photodynamic therapy (PDT) of vulnerable plaque using two pluralities of nanoparticles, one plurality comprising a PDT agent that is sensitive to blue-green light wherein the nanoparticles are capable of penetrating only into the fibrous cap of the vulnerable plaque and one plurality comprising a PDT agent that is sensitive to red light wherein the nanoparticles are capable of penetrating into the core of the vulnerable plaque.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: February 21, 2017
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Syed Hossainy, Dariush Davalian, Mikael Trollsas, John Stankus, Jinping Wan
  • Patent number: 9555111
    Abstract: Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 31, 2017
    Assignee: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 9517239
    Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: December 13, 2016
    Assignee: Infacare Pharmaceutical Corporation
    Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
  • Patent number: 9480657
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum compound having a heterocycle ligand. Cabazitaxel-platinum nanoparticles are disclosed herein, as well as methods of making and using the same.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 1, 2016
    Assignee: Tarveda Therapeutics, Inc.
    Inventors: Mark T. Bilodeau, Craig A. Dunbar, Timothy E. Barder, Edward R. Lee, Rossitza G. Alargova, Danielle N. Rockwood
  • Patent number: 9365593
    Abstract: The present invention provides compounds of Formula I: along with compositions comprising the same and methods of using the same, such as for photodynamic therapy in the treatment of cancer.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: June 14, 2016
    Assignee: Duke University
    Inventors: Katherine J. Franz, Katie L. Ciesienski
  • Patent number: 9309247
    Abstract: The present invention provides 2-substituted imidazo[4,5-d]phenanthroline compounds, which are capable of inhibiting proliferation of one or more renal cancer cells, pancreatic cancer cells, prostate cancer cells, colon cancer cells, leukemia cells, brain cancer/tumor cells or non-small cell lung cancer cells.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 12, 2016
    Assignee: LORUS THERAPEUTICS INC.
    Inventors: Yoon Lee, Howard Cukier, Venkata Nedunuri, Robert Peralta, Mario Huesca, Aiping H. Young
  • Patent number: 9289434
    Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 22, 2016
    Assignees: Aeolus Sciences, Inc., National Jewish Health, Duke University
    Inventors: James D. Crapo, Brian J. Day, Michael P. Trova, Polivina Jolicia F. Gauuan, Douglas B. Kitchen, Irwin Fridovich, Ines Batinic-Haberle
  • Patent number: 9290528
    Abstract: The presently-disclosed subject matter includes light-activated ruthenium compounds. In some embodiments the compounds release one or more ligands when exposed to light, and in specific embodiments the light includes a wavelength of about 500 nm to about 1000 nm. The present compounds can also comprise an overall charge, wherein the overall charge can be a positive overall charge or a negative overall charge. Further still, embodiments include methods of treating cancer in a subject by administering a compound and then exposing a site of the subject to light.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: March 22, 2016
    Assignee: University of Kentucky Research Foundation
    Inventors: Edith C. Glazer, David K. Heidary
  • Patent number: 9222922
    Abstract: A high performance liquid chromatography method to routinely and reproducibly detect and quantitate metal complexes is provided. The metal complexes used in the method of the invention can be different metal complexes, or they can be stereoisomers of the same metal complexes. The high performance liquid chromatography method of the present invention is suitable for the separation of diastereomers of the same metal complexes. Also provided is a chiral high performance liquid chromatography method to separate enantiomers of metal complexes. Superoxide dismutase mimetic compounds are also provided.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: December 29, 2015
    Assignee: Galera Labs, LLC
    Inventors: Urszula J. Slomczynska, Bobby N. Trawick, Dennis P. Riley, Arati Naik
  • Patent number: 9149483
    Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: October 6, 2015
    Assignee: GALERA LABS, LLC
    Inventors: Jeffery L. Keene, Dennis P. Riley, Robert A. Beardsley
  • Patent number: 9150837
    Abstract: Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds are also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: October 6, 2015
    Assignee: GALERA LABS LLC
    Inventors: Daniela Salvemini, William L. Neumann, Samuel Tremont, Kishore Udipi, Amruta Reddy Poreddy
  • Patent number: 9107927
    Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: August 18, 2015
    Assignee: Infacare Pharmaceutical Corporation
    Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
  • Patent number: 9090640
    Abstract: Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, C1-6alkylene-phenyl-NH—C(O)—R15, folic acid, ?v?3 integrin RGD binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein R15 is a peptide.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: July 28, 2015
    Inventors: Ulrich Bierbach, Song Ding
  • Patent number: 9034862
    Abstract: The present invention relates to compositions, kits, and methods for treatment of cancers. In some cases, the composition comprises a platinum compound comprising a phenanthridine ligand.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: May 19, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Stephen J. Lippard, Ga Young Park
  • Publication number: 20150125550
    Abstract: A method of inhibiting cancer cell growth is provided. In some versions, the method includes exposing lung cancer cells or glioma cells to 2,9-di-sec-butyl-1,10-phenanthroline (SBP) or derivatives of SBP in an amount effective to inhibit glioma cell growth. Also, a method of treating a lung cancer or a glioma tumor in a subject in need of such treatment is provided. The method includes administering SBP or derivatives of SBP to the subject in an amount effective to treat the lung cancer or glioma tumor. For either method, the method can further include exposing or administering pseudo five coordinate gold(III) complexes of SBP derivatives.
    Type: Application
    Filed: August 29, 2014
    Publication date: May 7, 2015
    Inventors: Jack F. Eichler, Clement N. David, Emma H. Wilson
  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 9011933
    Abstract: A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments.
    Type: Grant
    Filed: January 23, 2005
    Date of Patent: April 21, 2015
    Assignee: Biomas Ltd.
    Inventors: Benjamin Sredni, Michael Albeck
  • Publication number: 20150087612
    Abstract: Compounds having the general structural formula (I) wherein X can be any element or compound that can form a coordination complex with phthalocyanine and wherein R1; R2, R3 and R4 are independently anionic moieties, or (II) wherein R1; R2, R3 and R4 are independently anionic moieties, are useful in the potentiation of antibiotic activity, and/or in inhibiting or delaying the development of resistance to antibiotics. R1; R2, R3 and R4 may be —S03-. The compounds may be administered to a subject in conjunction with an antibiotic. The antibiotic may be an activator of the SOS response, and may be a DNA gyrase inhibitor or a topoisomerase inhibitor. Compositions and dosage forms comprising the compounds are provided.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 26, 2015
    Inventors: Clarence Ronald Geyer, Yu Luo
  • Publication number: 20150064120
    Abstract: The present invention relates to the cosmetic use, as an antidandruff agent, of catalytic oxidation compounds chosen from porphyrins, or of a cosmetic composition comprising the same.
    Type: Application
    Filed: February 22, 2013
    Publication date: March 5, 2015
    Inventor: Henri Samain
  • Patent number: 8968715
    Abstract: The invention is generally related to the field of photodynamic therapy by use of photosensitizers and stabilized formulations of the photosensitizers. These formulations may be used to deliver a photosensitizer as a pharmaceutical, agricultural, or industrial agent. The photosensitizer containing formulations and compositions of the invention comprise one or more block copolymers. Furthermore, the invention relates to processes for the production of, and application of, said formulations and compositions as photosensitizer drug delivery systems.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: March 3, 2015
    Assignee: The University of British Columbia
    Inventors: Rubinah K. Chowdhary, David Dolphin
  • Patent number: 8951969
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: February 10, 2015
    Assignee: Helsinn Healthcare SA
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Patent number: 8946463
    Abstract: The present invention relates to a chemocatalytic liquid-phase process for the direct one-stage amination of alcohols to primary amines by means of ammonia in high yields using a catalyst system containing at least one transition metal compound and a xantphos ligand.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: February 3, 2015
    Assignee: Evonik Degussa GmbH
    Inventors: Florian Klasovsky, Thomas Tacke, Jan Christoph Pfeffer, Thomas Haas, Matthias Beller, Andreas Martin, Jens Deutsch, Angela Koeckritz, Sebastian Imm, Juergen Haberland
  • Patent number: 8946202
    Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: February 3, 2015
    Assignees: Aeolus Sciences, Inc., National Jewish Health, Duke University
    Inventors: James D. Crapo, Brian J. Day, Michael P. Trova, Polvina Jolicia Gauuan, Douglas B. Kitchen, Irwin Fridovich, Ines Batinic-Haberle
  • Patent number: 8940723
    Abstract: This invention relates to the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof in combination with another antimicrobial agent selected from the group consisting of a beta-lactam antimicrobial agent, mupirocin and chlorhexidine or a pharmaceutically acceptable derivative thereof, for the prevention and/or treatment of microbial infections.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: January 27, 2015
    Assignee: Helperby Therapeutics Limited
    Inventors: Yanmin Hu, Anthony R. M. Coates
  • Publication number: 20150023914
    Abstract: Methods for treating skin conditions such as basal cell carcinoma and/or actinic keratosis are provided, which are effected by administering a pharmaceutically effective amount of a tellurium-containing compound. A pharmaceutical composition for treatment of skin conditions such as basal cell carcinoma and/or actinic keratosis is also provided.
    Type: Application
    Filed: April 21, 2014
    Publication date: January 22, 2015
    Applicant: BioMAS Ltd.
    Inventors: Benjamin SREDNI, Michael ALBECK
  • Publication number: 20140377289
    Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Inventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
  • Publication number: 20140378427
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum compound having a heterocycle ligand. Cabazitaxel-platinum nanoparticles are disclosed herein, as well as methods of making and using the same.
    Type: Application
    Filed: March 17, 2014
    Publication date: December 25, 2014
    Applicant: Blend Therapeutics
    Inventors: Mark T. Bilodeau, Craig A. Dunbar, Timothy E. Barder, Edward R. Lee, Rossitza G. Alargova, Danielle N. Rockwood
  • Publication number: 20140371192
    Abstract: The present invention relates to alpha-form zinc-phthalocyanine nanowires (ZnPc NWs) having enhanced water solubility and water dispersibility, to a composite of an alpha-form zinc-phthalocyanine nanowire/phenothiazine, to a method for preparing same, and to a photosensitizer including same or a pharmaceutical composition including same for preventing or treating cancers. Since the alpha-form zinc-phthalocyanine nanowires or the composite of alpha-form zinc-phthalocyanine nanowire/phenothiazine according to the present invention exhibit dual traits, i.e., photothermal and photodynamic traits in single molecules, they are very useful for the development of a multifunctional molecular system and can also be usefully applied to light therapy of cancers due to their good light therapeutic effects.
    Type: Application
    Filed: August 30, 2012
    Publication date: December 18, 2014
    Applicant: POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY INDUSTRYACADEMY COOPERATION CORPS
    Inventors: Hee Cheul Choi, Hye Kyung Moon, Sang Ho Lee
  • Publication number: 20140364406
    Abstract: One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and/or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free fatty acids, and identifying compounds suitable for treatment or prevention of ROS-mediated injury are also disclosed.
    Type: Application
    Filed: July 28, 2014
    Publication date: December 11, 2014
    Inventors: Geoffrey C. Gurtner, Michael A. Brownlee
  • Patent number: 8906897
    Abstract: The invention relates to novel antimicrobial, including antibacterial and antifungal, agents and compositions based on hemin derivatives of general formula (I), and also to the production of novel hemin derivatives. The advantages of antibacterial agents based on hemin derivatives are their biocompatibility, biodegradability, high effectiveness against resistant bacteria and widespread microfungi that are harmful to humans, and freedom from toxicity and side effects.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: December 9, 2014
    Assignee: Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises”
    Inventors: Vladimir Evgenievich Nebolsin, Galina Alexandrovna Zheltukhina
  • Patent number: 8906896
    Abstract: Acridine containing cisplatin compounds are disclosed that show greater efficacy than other cisplatin compounds for treating cancer. The compounds are compounds of Formula I wherein the variables are defined herein.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: December 9, 2014
    Inventor: Ulrich Bierbach
  • Patent number: RE47123
    Abstract: Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: November 13, 2018
    Assignee: SANOFI
    Inventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli